- Home
- NLOP vs ANTX Comparison
NLOP vs ANTX Comparison
Compare NLOP & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NLOP | ANTX |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.9M | 172.9M |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | NLOP | ANTX |
|---|---|---|
| Price | $10.47 | $5.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 101.4K | ★ 186.3K |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | ★ 52.20% | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $118,915,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.37 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.60 | $1.00 |
| 52 Week High | $30.26 | $7.19 |
Technical Indicators
Market Signals| Indicator | NLOP | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 27.02 | 36.32 |
| Support Level | N/A | $3.91 |
| Resistance Level | $11.65 | $5.15 |
| Average True Range (ATR) | 0.27 | 0.34 |
| MACD | -0.06 | -0.11 |
| Stochastic Oscillator | 14.27 | 12.50 |
Price Performance
Historical ComparisonAbout NLOP Net Lease Office Properties of Beneficial Interest
Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns, operates, and finances a diversified portfolio of office properties mainly leased to corporate tenants on a single-tenant, net-lease basis. The company operates as a single operating and reportable segment focused on owning and managing office properties that generate revenue mainly from long-term lease agreements with tenants.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.